Logo Image
  • News
  • Media
  • Conferences
  • Publications
  • Events
  • CE
  • Resources
  • Subscribe

Mark N. Sorial, PharmD, BCOP

Articles by Mark N. Sorial, PharmD, BCOP

B-cell lymphoma -- Image credit: Arif Biswas | stock.adobe.com

Bispecific T-Cell–Engaging Antibodies in B-Cell Lymphoma: Efficacy, Safety, and Practical Considerations

ByUvette Lou, PharmD, BCOP,Brenna Rowan, PharmD, BCOP,Abigail McLaren, PharmD, MS,E. Bridget Kim, PharmD, BCPS, BCOP,Mark N. Sorial, PharmD, BCOP,J. Erika Haydu, MD, PhD,Matthew M. Lei, PharmD, BCOP

Peer Reviewed

This article reviews the efficacy and safety data for bispecific T-cell engagers and the practical considerations for their implementation across various types of practice sites for the historically difficult-to-treat relapsed/refractory B-cell lymphoma population.

Latest Updated Articles